Attana CEO Teodor Aastrup presents the company’s most recent progress at Erik Pensers Company Day (“Bolagsdag”) September 24[th]

Follow the presentation here. It will be a 20-minute presentation between 11.35 and 11.55 covering the following topics:

• Introduction to Attana
• Recruitment of Niklas Carlsson as COO and VP
• Progress of communication and marketing efforts
• Ongoing work with the current product offering: Contract Research and Instrument Sales
• Update on Attana Diagnostic projects (AVA):
  • Results of Attana COVID-19 diagnostics study
  • Results of Attana Tetanus diagnostics study
  • Results of Attana diagnostics study using whole blood
  • Technical interpretation and commercial implications of the results

For more information, please contact:

Teodor Aastrup, CEO Attana AB
e-mail: teodor.aastrup@attana.com 
tel: + 46 8 674 57 00

The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price, but is of general interest for the shareholders and hence should be communicated.

Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays. Attana’s products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about Attana’s contract research services and our label free cell-based biosensors, please visit www.attana.com or contact sales@attana.com

Tags: